英国全国注册研究:开窗腔内动脉瘤修复术的长期结局
基于英国GLOBALSTAR注册库(2003-2022)分析1651例接受定制开窗腔内修复术(FEVAR)的肾下腹主动脉瘤患者,中位生存6.9年,10年动脉瘤相关死亡6.4%,7年再干预累积发生率27.6%,移植物相关并发症占再干预的74.5%。女性2年生存显著低于男性, octogenarians与非octogenarians 1年生存无显著差异。
要点
- FEVAR长期生存可接受,10年动脉瘤相关死亡仅6.4%,继发囊破裂罕见(36例)。
- 再干预风险显著,7年累积27.6%,其中74.5%为移植物相关并发症。
- 女性2年生存显著劣于男性(81.1% vs 86.1%,P=0.041),源于围术期死亡增加。
核心结论
- FEVAR长期结局可接受,继发囊破裂率低,但再干预风险显著,移植物相关并发症是主要驱动因素,有效规划和移植物监测对长期耐久性至关重要。
研究设计与样本
- 分析英国GLOBALSTAR注册库(2003-2022)中15个中心、1651例因肾下腹主动脉瘤性疾病接受定制开窗腔内修复术(FEVAR)的患者,排除I-III型胸腹主动脉瘤及其他复杂EVAR技术,采用时间-事件分析。
主要发现
- 中位年龄75岁(IQR 69-79),男性占87.9%。
- 3年、5年、10年估计生存率分别为79.5%(95%CI 77.6%-81.5%)、64.1%(95%CI 61.7%-66.6%)、30.5%(95%CI 27.7%-33.5%),中位生存6.9年(95%CI 6.6-7.2)。
- 10年动脉瘤相关死亡率为6.4%(95%CI 5.1%-7.7%),随访期间继发囊破裂36例。
- 3年、5年、7年再干预累积发生率分别为21.5%(95%CI 19.5%-23.6%)、25.6%(95%CI 23.4%-27.8%)、27.6%(95%CI 25.3%-30.0%),移植物相关并发症占再干预的74.5%。
- 女性2年生存率81.1%(95%CI 75.8%-86.8%)显著低于男性86.1%(95%CI 84.3%-87.9%)(P=0.041),由围术期死亡率增加驱动;2年后生存差异无统计学显著性。
临床怎么用
- FEVAR适用于解剖条件不适合标准EVAR的肾下腹主动脉瘤患者,长期生存可接受但需重视再干预风险。
- 应加强术前规划和术后移植物监测,以早期发现移植物相关并发症并降低再干预率。
- 女性患者围术期风险较高,需更谨慎的围术期管理;年龄≥80岁患者经选择后手术风险与年轻患者相当。
局限性
- 本研究为注册库回顾性分析,可能存在选择偏倚和未测量混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fenestrated endovascular aneurysm repair (FEVAR) is increasingly used in patients who are not eligible for standard endovascular aneurysm repair (EVAR) devices due to anatomical constraints, principally of the proximal aortic neck. The long-term outcomes of FEVAR are not well described and therefore the aim of this study was to perform an analysis of a national registry in the UK. METHODS: The UK GLOBALSTAR registry (2003-2022) was analysed to report the long-term outcomes of FEVAR. Patients were included if they underwent FEVAR with custom-made devices for infradiaphragmatic aortic aneurysmal disease. Patients with extent I-III thoracoabdominal aneurysms or those who underwent other complex EVAR techniques were excluded. Time-to-event analyses were conducted for survival, aneurysm-related mortality, reintervention, endoleak, and target vessel patency. Subgroup analyses were conducted for octogenarians and patient sex. RESULTS: Some 1651 patients across 15 centres were included. The median age was 75 (interquartile range 69-79) years and 87.9% were male. Estimated survival at 3, 5, and 10 years was 79.5% (95% c.i. 77.6% to 81.5%), 64.1% (95% c.i. 61.7% to 66.6%), and 30.5% (95% c.i. 27.7% to 33.5%) respectively; median survival was 6.9 (95% c.i. 6.6 to 7.2) years. Aneurysm-related mortality was 6.4% (95% c.i. 5.1% to 7.7%) at 10 years. There were 36 secondary sac ruptures over follow-up. The cumulative incidence of reintervention at 3, 5, and 7 years was 21.5% (95% c.i. 19.5% to 23.6%), 25.6% (95% c.i. 23.4% to 27.8%), and 27.6% (95% c.i. 25.3% to 30.0%) respectively. Graft-related complications accounted for 74.5% of reinterventions. Women had significantly worse 2-year survival (81.1% (95% c.i. 75.8% to 86.8%)) than men (86.1% (95% c.i. 84.3% to 87.9%)) (P = 0.041), driven by increased perioperative mortality. Beyond 2 years, the differences in survival were not statistically significant. Octogenarians had equivalent survival (89.4% (95% c.i. 86.4% to 92.4%)) to non-octogenarians (92.1% (95% c.i. 90.7% to 93.6%)) up to 1 year (P = 0.074). Octogenarians' median survival was 5.4 (95% c.i. 5.0 to 6.1) years. CONCLUSIONS: Long-term outcomes of FEVAR appear acceptable, with low rates of secondary sac rupture. FEVAR is associated with a significant risk of reintervention, with graft-related complications being a key driver, suggesting effective planning and graft surveillance are key to long-term durability. BACKGROUND: WHY DO THIS RESEARCH?: An abdominal aortic aneurysm (AAA) is a swelling of the main blood vessel in the abdomen (tummy) and affects thousands of people each year. AAAs can grow over time and may burst. If the swelling gets too large, people are offered an operation to repair the swollen blood vessel to stop it bursting. This used to involve an operation that cut open the abdomen, but now surgeons can use keyhole methods to place a small metal mesh tube (stent) inside the swollen blood vessel instead. AAAs come in all shapes and sizes, and around a third of AAAs have awkward shapes that need a ‘complex’ keyhole method called a fenestrated endovascular aneurysm repair (FEVAR). In this operation, the stent needs to be custom-made to fit the awkward shape of the AAA, rather than using an off-the-shelf stent, which can be used for more common AAA shapes. Despite thousands of complex repairs taking place each year worldwide, it is not known what the long-term recovery after this operation is or if people live as long as people having other types of operations. To try to understand this, 15 UK hospitals have teamed up to record when they do these complex operations, how patients recover afterwards, and if they need further operations. The register is called the GLOBALSTAR registry. AIMS: First, to find out the long-term results for FEVAR: how long do people live for, how many people have a reoperation, and how do older patients aged ≥80 years fare after the operation? Second, how do women fare after the operation? METHODS: The authors used information in the registry and statistics to describe the long-term results for FEVAR. FINDINGS AND CONCLUSION: WHAT DID THE AUTHORS FIND?: It was found that, after the operation, people will live on average for 7 years and around a quarter will need a reoperation within 7 years. The main reasons for needing a reoperation are technical issues with the device itself, which account for three-quarters of reasons to reoperate. The procedure was riskier for women, with twice the risk of a complication immediately after the operation compared with men. In contrast, patients aged ≥80 years had a similar level of risk related to surgery compared with younger patients and around 90% were still alive at 1 year after the operation. After the operation, patients aged ≥80 years survived >5 years on average; this probably means that patients and doctors are good at deciding who should go forward with surgery in this age group. This study suggests that FEVAR is a good option for repairing AAAs in the right people. Lowering the risk of reoperation is really important; planning the operation carefully and checking up on patients to pick up any issues with the device are important areas to improve on. Getting these things right will make care for people with AAAs better.
引用
- Guéroult AM. Nationwide outcomes of fenestrated endovascular aneurysm repair. Br J Surg. 2026. PMID: 41894566. doi:10.1093/bjs/znag037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。